Consolidated Financial Results for the Fiscal Year 2024
(Year ended March 31, 2025)
May 13, 2024
Kaken Pharmaceutical Co., Ltd.
Cautionary notes regarding forward-looking statement
The performance forecasts described in this material are rational based on the information currently available and have been determined by the Company as reasonable.
Considerable financial investment and a long development time are required before a new drug is launched. The Company carefully develop new drugs by confirming their efficacy and safety. There is a possibility that their development may be discontinued before completion, in such case where anticipated efficacy has not been proven or safety issues have been identified.
The "Projects under Development" is based on the current development plans.
The status may change depending on their progress.
The information about pharmaceutical products (including those under development) included in this material is not intended as an advertisement or medical advice.
Agenda
1
3
4
2
Consolidated Financial Results for FY2024 Consolidated Financial Forecast for FY2025 Progress on "Long-Term Business Plan 2031"
Updates on "Actions to Implement Management that is
Conscious of Cost of Capital and Stock Price"
5
Updates on Research and Development
1
Consolidated Financial Results for FY2024
Consolidated Statements of Income
(amounts are rounded down to the nearest million yen)
FY2023 | FY2024 | YoY Change | Change (%) | Plan FY2024 * | Change (%) | |
Net Sales | 72,044 | 94,035 | 21,990 | 130.5 | 94,000 | 100.0 |
Cost of Sales | 33,505 | 35,502 | 1,997 | 106.0 | ー | ー |
Gross Profit | 38,539 | 58,532 | 19,993 | 151.9 | ー | ー |
Selling, General and Administrative Expenses | 29,025 | 37,497 | 8,471 | 129.2 | ー | ー |
R&D Expenses | 12,543 | 18,725 | 6,182 | 149.3 | ー | ー |
Operating Profit | 9,513 | 21,034 | 11,521 | 221.1 | 20,800 | 101.1 |
Ordinary Profit | 9,951 | 21,279 | 11,328 | 213.8 | 21,000 | 101.3 |
Profit before Income Tax | 9,796 | 19,435 | 9,639 | 198.4 | ー | ー |
Profit | 8,025 | 13,945 | 5,919 | 173.8 | 14,000 | 99.6 |
（*: Revised forecast announced on April 8, 2025）